MARKET

SILK

SILK

Silk Road Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.69
-1.46
-2.55%
After Hours: 55.69 0 0.00% 16:00 09/24 EDT
OPEN
57.05
PREV CLOSE
57.15
HIGH
57.05
LOW
55.54
VOLUME
177.20K
TURNOVER
--
52 WEEK HIGH
75.80
52 WEEK LOW
43.11
MARKET CAP
1.93B
P/E (TTM)
-39.3847
1D
5D
1M
3M
1Y
5Y
President And CEO Of Silk Road Medical Trades $648.17 Thousand In Company Stock
Erica Rogers, President And CEO at Silk Road Medical (NASDAQ:SILK), made a large buy and sell of company shares on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on ...
Benzinga · 09/15 14:50
Silk Road Medical Inc (SILK) President and CEO Erica J. Rogers Sold $630,520 of Shares
GuruFocus News · 09/15 12:15
BRIEF-Silk Road Says Throughout Q3 Procedure Volumes Continue To Be Impacted By Increased Hospitalizations
reuters.com · 09/13 13:40
Silk Road Medical to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
SUNNYVALE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming ...
GlobeNewswire · 09/01 20:10
Silk Road Medical Inc (SILK) EVPClin&Reg.Affairs&QA Richard Ruedy Sold $847,385 of Shares
GuruFocus News · 08/31 12:15
Deerfield Management Company, L.p. (series C) Buys Singular Genomics Systems Inc, CareMax Inc, ...
GuruFocus News · 08/24 19:38
First Ever Analysis of TCAR in Standard Surgical Risk Patients Demonstrates Clinical Benefits in Large Comparative Dataset
Large-Scale Analysis of TCAR in The Treatment of Standard Surgical Risk Patients Presented at The Society for Vascular Surgery 2021 Vascular Annual Meeting
GlobeNewswire · 08/18 20:15
Silk Road Medical Inc (SILK) President and CEO Erica J. Rogers Sold $540,320 of Shares
GuruFocus News · 08/13 16:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SILK. Analyze the recent business situations of Silk Road Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SILK stock price target is 62.50 with a high estimate of 75.00 and a low estimate of 50.00.
EPS
Institutional Holdings
Institutions: 214
Institutional Holdings: 38.13M
% Owned: 109.93%
Shares Outstanding: 34.68M
TypeInstitutionsShares
Increased
63
2.92M
New
15
1.39M
Decreased
51
2.78M
Sold Out
31
1.27M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.61%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Non-Executive Chairman/Independent Director
Jack Lasersohn
President/Chief Executive Officer/Director
Erica Rogers
Chief Financial Officer/Chief Operating Officer
Lucas Buchanan
Executive Vice President
Richard Ruedy
General Counsel
William Hill
Other
Andrew Davis
Director
Tanisha Carino
Independent Director
Rick Anderson
Independent Director
Kevin Ballinger
Independent Director
Tony Chou
Independent Director
Elizabeth Weatherman
Independent Director
Donald Zurbay
No Data
About SILK
Silk Road Medical, Inc. is a medical device company. The Company has developed an approach for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). The Company’s TCAR relies on two concepts - minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines the benefits of endovascular techniques with fundamental surgical principles. The Company’s ENROUTE Transcarotid Neuroprotection System (NPS) and ENROUTE Transcarotid Stent System are the products for use in TCAR. The ENROUTE Transcarotid Stent is indicated for use in High Surgical Risk patients and is designed to be used in conjunction with the ENROUTE NPS during the TCAR procedure. The ENROUTE Transcarotid NPS is a device used to access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.

Webull offers kinds of Silk Road Medical Inc stock information, including NASDAQ:SILK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SILK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SILK stock methods without spending real money on the virtual paper trading platform.